galantamine has been researched along with Neurodegenerative Diseases in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gaube, F; Heilmann, J; Lehmann, J; Rook, Y; Schepmann, D; Schmidtke, KU; Winckler, T; Wünsch, B | 1 |
| Amoroso, R; Carradori, S; De Filippis, B; Fantacuzzi, M | 1 |
| Majidazar, R; Naseri, A; Rezazadeh-Gavgani, E; Sadigh-Eteghad, S | 1 |
| Metz, CN; Pavlov, VA | 1 |
| Emad Aboulhoda, B; Gamal, M; Magdy, S; Mohammed, HS; Rashed, L; Samir, NF; Sharawy, N | 1 |
| Calderó, G; Feiner-Gracia, N; Fornaguera, C; García-Celma, MJ; Solans, C | 1 |
| Shimohama, S | 1 |
| Cummings, JL; Ringman, JM | 1 |
5 review(s) available for galantamine and Neurodegenerative Diseases
| Article | Year |
|---|---|
Resveratrol-based compounds and neurodegeneration: Recent insight in multitarget therapy.
Topics: Humans; Neurodegenerative Diseases; Polyphenols; Resveratrol; Stilbenes; Structure-Activity Relationship | 2022 |
Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews.
Topics: Alzheimer Disease; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Cholinesterase Inhibitors; Donepezil; Galantamine; Glycogen Synthase Kinase 3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Indans; Lithium; Melatonin; Memantine; Neurodegenerative Diseases; Rivastigmine; Systematic Reviews as Topic | 2022 |
Treating disorders across the lifespan by modulating cholinergic signaling with galantamine.
Topics: Acetylcholinesterase; Animals; Anti-Inflammatory Agents; Brain; Cholinergic Agents; Cholinesterase Inhibitors; Galantamine; Humans; Longevity; Mental Disorders; Neurodegenerative Diseases | 2021 |
Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Amyloid beta-Peptides; Animals; Drug Synergism; Galantamine; Glutamic Acid; Motor Neurons; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinson Disease, Secondary; Phosphatidylinositol 3-Kinases; Rats; Receptors, Nicotinic; Rotenone; Signal Transduction; Spinal Cord | 2009 |
Current and emerging pharmacological treatment options for dementia.
Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2006 |
3 other study(ies) available for galantamine and Neurodegenerative Diseases
| Article | Year |
|---|---|
Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents.
Topics: Alzheimer Disease; Butyrylcholinesterase; Carbolines; Cholinesterase Inhibitors; Excitatory Amino Acid Antagonists; Humans; Inhibitory Concentration 50; Memantine; Neurodegenerative Diseases; Receptors, N-Methyl-D-Aspartate | 2010 |
IκB kinase inhibition remodeled connexins, pannexin-1, and excitatory amino-acid transporters expressions to promote neuroprotection of galantamine and morphine.
Topics: Animals; Anti-Inflammatory Agents; Brain; Connexins; Disease Models, Animal; Excitatory Amino Acid Transporter 1; Excitatory Amino Acid Transporter 2; Galantamine; Glutamic Acid; I-kappa B Kinase; Lipopolysaccharides; Male; Morphine; Nerve Tissue Proteins; Neurodegenerative Diseases; Neuroglia; Neurons; Neuroprotection; Neuroprotective Agents; Nitriles; Rats, Sprague-Dawley; Signal Transduction; Sulfones | 2021 |
Galantamine-loaded PLGA nanoparticles, from nano-emulsion templating, as novel advanced drug delivery systems to treat neurodegenerative diseases.
Topics: Cholinesterase Inhibitors; Drug Carriers; Emulsions; Galantamine; HeLa Cells; Humans; Lactic Acid; Nanoparticles; Neurodegenerative Diseases; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2015 |